Skip to main content

Matthew J. Gardella

Mergers & Acquisitions

  • QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) in its $11.5 billion sale to Thermo Fisher Scientific, Inc. (NYSE: TMO)
  • Netsmart's acquisition of healthcare advisory firm, McBee Associates 
  • Synlogic, Inc. in its merger with Mirna Therapeutics, Inc. (Nasdaq: MIRN)
  • Molecular Templates, Inc. in its merger with Threshold Pharmaceuticals, Inc. (Nasdaq: THLD)
  • Synta Pharmaceuticals (Nasdaq: SNTA) in its merger with Madrigal Pharmaceuticals
  • Atlantic Tele-Network (Nasdaq: ATNI) in its $145 million acquisition of Innovative Group
  • Netsmart Technologies, Inc. in multiple acquisitions, including of HealthMEDX; Lavender & Wyatt Systems; Trend Consulting Services; Defran Systems; and Sequest Technologies
  • Essilor International SA in its $270 million acquisition of Costa Inc. (Nasdaq: ATX)
  • FGX International in its acquisition of Stylemark
  • ASSA ABLOY AB in its $80 million acquisition of LaserCard Corporation (Nasdaq: LCRD)
  • ABRY Partners, a private equity firm, in its $1.3 billion acquisition of RCN Corporation (Nasdaq: RCNI)
  • Cequent Pharmaceuticals in its sale to Marina Biotech, Inc. (Nasdaq: MRNAD), formerly known as MDRNA, Inc.
  • Dynasil Corporation of America (Nasdaq: DYSL) in its acquisition of Hilger Crystal Limited, a U.K. subsidiary of Newport Corp. (Nasdaq: NEWP)
  • Management team of Netsmart Technologies, Inc. in connection with the acquisition of Netsmart by private equity firm, Genstar Capital, including terms of management’s “roll-over” and co-investment arrangements and related employment and compensation arrangements
  • Takeda Pharmaceutical Company Limited (TSE:4502) in its $8.8 billion acquisition of Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM), one of the largest foreign acquisitions by a Japanese company, the largest by a Japanese company in the pharmaceutical industry and IDD magazine‘s “Healthcare Deal of the Year” in 2008
  • Lane, Berry & Co. International LLC in its sale to Raymond James Financial, Inc.
  • Netsmart Technologies, Inc. in its acquisition of the assets of the Therapist Helper Division from Nightingale Informatix Corporation (TSX-V:  NGH)
  • XIUS – bcgi in its sale of substantially all of its interests in its Israeli subsidiary, Puresight Technologies Limited
  • Boston Communications Group, Inc. (Nasdaq: BCGI) in its $65 million merger with Megasoft Limited
  • Helix Technology Corporation (Nasdaq: HELX) in its agreement to merge with Brooks Automation in a $450 million stock swap

Securities Offerings

  • Spero Therapeutics, Inc. in its $75 million follow-on offering, its $10 million registered direct offering and its $30 million rights offering
  • Molecular Templates, Inc. in its $52 million follow-on offering
  • Adaptimmune Therapeutics plc in its $100 million follow-on offering (investors' counsel)
  • Synlogic, Inc. in its $57.5 million follow-on offering and its $30 million registered direct offering 
  • Spero Therapeutics, Inc. in its $83.6 million IPO
  • WAVE Life Sciences Ltd. in its $102 million IPO
  • Achillion Pharmaceuticals, Inc. in its $141.4 million follow-on offering (underwriters' counsel)
  • TECO Energy in its $280.5 million public offering of common stock
  • Stemline Therapeutics, Inc. in its $30 million IPO
  • Recapitalization transaction of SofTech, Inc.
  • Atlantic Tele-Network in its $68 million public offering of common stock
Case Study
Mintz represented Synlogic in an $80 million financing from Ginkgo Bioworks and the parties' related collaboration to expand development of Synlogic’s Synthetic Biotic medicines. Mintz previously helped Synlogic raise over $200 million in capital, plus another $40 million through a reverse merger.
Case Study
Mintz advised biopharma company Spero Therapeutics on an agreement with Everest Medicines regarding the development and commercialization of a product to treat multidrug-resistant bacterial infections and option to license another.
Case Study
In July 2018 Mintz represented Spero Therapeutics, a multi-asset clinical stage biopharmaceutical company, in its underwritten public offering. The offering included 3,780,000 shares of its common stock and 2,220 shares of its non-voting Series A Convertible Preferred Stock, with the gross proceeds to Spero being $75M prior to the deduction of any underwriting discounts and commissions.
Case Study
Mintz’s work for synthetic biotic company Synlogic Inc. has included raising over $100 million in three VC financing rounds. Mintz attorneys also helped Synlogic form a multiyear global R&D collaboration with AbbVie and raise more than $40 million in an IPO via a reverse merger with Mirna Therapeutics.